(Q40166479)

18 September 2017

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice (English)

1 reference

18 September 2017

1 reference

Aya Jakobovits

1

1 reference

18 September 2017

Rafael G Amado

2

1 reference

18 September 2017

Xiaodong Yang

3

1 reference

18 September 2017

Lorin Roskos

4

1 reference

18 September 2017

Gisela Schwab

5

1 reference

18 September 2017

1 October 2007

1 reference

18 September 2017

1 reference

18 September 2017

25

1 reference

18 September 2017

1134-1143

1 reference

18 September 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt1337

18 September 2017

0 references

cites work

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

7 January 2021

1 reference

7 January 2021

Reshaping human antibodies for therapy

1 reference

7 January 2021

Selecting and screening recombinant antibody libraries

1 reference

7 January 2021

Human antibodies from transgenic animals

1 reference

7 January 2021

Analysis of homozygous mutant chimeric mice: deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production

1 reference

7 January 2021

Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes

1 reference

7 January 2021

Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs

1 reference

7 January 2021

Organization of the human immunoglobulin heavy-chain locus

1 reference

7 January 2021

The human immunoglobulin VH repertoire

1 reference

7 January 2021

Analysis of the structural integrity of YACs comprising human immunoglobulin genes in yeast and in embryonic stem cells

1 reference

7 January 2021

Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice

1 reference

7 January 2021

The human immunoglobulin kappa locus consists of two copies that are organized in opposite polarity

1 reference

7 January 2021

Germ-line transmission and expression of a human-derived yeast artificial chromosome

1 reference

7 January 2021

Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics

1 reference

7 January 2021

The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans

1 reference

7 January 2021

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice.

1 reference

7 January 2021

Antigen-specific human antibodies from mice comprising four distinct genetic modifications

1 reference

7 January 2021

Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma

1 reference

7 January 2021

A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis

1 reference

7 January 2021

Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.

1 reference

7 January 2021

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

1 reference

7 January 2021

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

1 reference

7 January 2021

Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study.

1 reference

7 January 2021

Epidermal growth factor receptor targeting in cancer

1 reference

7 January 2021

EGFR in colorectal cancer: more than a simple receptor

1 reference

7 January 2021

Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors

1 reference

7 January 2021

High-affinity epidermal growth factor binding is specifically reduced by a monoclonal antibody, and appears necessary for early responses

1 reference

7 January 2021

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

7 January 2021

Untangling the ErbB signalling network

1 reference

7 January 2021

Sequencing the erbA gene of avian erythroblastosis virus reveals a new type of oncogene.

1 reference

7 January 2021

Ligand activation of overexpressed epidermal growth factor receptors transforms NIH 3T3 mouse fibroblasts

1 reference

7 January 2021

Epidermal growth factor receptor gene expression in normal human kidney and renal cell carcinoma

1 reference

7 January 2021

Expression of proto-oncogenes in normal and tumor tissues of human skin

1 reference

7 January 2021

Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues

1 reference

7 January 2021

Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical study

1 reference

7 January 2021

Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas

1 reference

7 January 2021

The EGF receptor family as targets for cancer therapy

1 reference

7 January 2021

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

7 January 2021

Panitumumab: in the treatment of metastatic colorectal cancer

1 reference

7 January 2021

Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy

1 reference

7 January 2021

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

1 reference

7 January 2021

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

1 reference

7 January 2021

Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

1 reference

7 January 2021

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

1 reference

7 January 2021

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

1 reference

7 January 2021

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

1 reference

7 January 2021

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

7 January 2021

Denosumab in postmenopausal women with low bone mineral density

1 reference

7 January 2021

A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

1 reference

7 January 2021

An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen

1 reference

7 January 2021

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

1 reference

7 January 2021

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

1 reference

7 January 2021

Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head

1 reference

7 January 2021

Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines

1 reference

7 January 2021

Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab

1 reference

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

7 January 2021

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

7 January 2021

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

7 January 2021

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

7 January 2021

The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus

1 reference

7 January 2021

Identifiers

DOI

10.1038/NBT1337

1 reference

18 September 2017

1 reference